Search
Now showing items 1-3 of 3
Targeting NaPi2b in ovarian cancer.
(ELSEVIER SCI LTD, 2023-01-01)
Novel biomarkers are needed to direct new treatments for ovarian cancer, a disease for which the standard of care remains heavily focused on platinum-based chemotherapy. Despite the success of PARP inhibitors, treatment ...
Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study.
(BMJ PUBLISHING GROUP, 2023-08-07)
OBJECTIVE: Olaparib plus bevacizumab maintenance therapy improves survival outcomes in women with newly diagnosed, advanced, high-grade ovarian cancer with a deficiency in homologous recombination. We report data from the ...
Low-grade serous ovarian cancer: expert consensus report on the state of the science.
(BMJ PUBLISHING GROUP, 2023-09-04)
Compared with high-grade serous carcinoma, low-grade serous carcinoma of the ovary or peritoneum is a less frequent epithelial ovarian cancer type that is poorly sensitive to chemotherapy and affects younger women, many ...